Cargando…
Novel Quinoline Compound Derivatives of NSC23925 as Potent Reversal Agents Against P-Glycoprotein-Mediated Multidrug Resistance
Multidrug resistance is a serious problem and a common cause of cancer treatment failure, leading to patient death. Although numerous reversal resistance inhibitors have been evaluated in preclinical or clinical trials, efficient and low-toxicity reversal agents have not been identified. In this stu...
Autores principales: | Quan, Xingping, Du, Hongzhi, Xu, Jingjing, Hou, Xiaoying, Gong, Xiaofeng, Wu, Yao, Zhou, Yuqi, Jiang, Jingwei, Lu, Ligong, Yuan, Shengtao, Yang, Xiangyu, Shi, Lei, Sun, Li |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6931887/ https://www.ncbi.nlm.nih.gov/pubmed/31921759 http://dx.doi.org/10.3389/fchem.2019.00820 |
Ejemplares similares
-
Prevention of multidrug resistance (MDR) in osteosarcoma by NSC23925
por: Yang, X, et al.
Publicado: (2014) -
NSC23925, Identified in a High-Throughput Cell-Based Screen, Reverses Multidrug Resistance
por: Duan, Zhenfeng, et al.
Publicado: (2009) -
Pharmacokinetics and tolerability of NSC23925b, a novel P-glycoprotein inhibitor: preclinical study in mice and rats
por: Gao, Yan, et al.
Publicado: (2016) -
Development of a Novel Quinoline Derivative as a P-Glycoprotein Inhibitor to Reverse Multidrug Resistance in Cancer Cells
por: Zhou, Yuanyuan, et al.
Publicado: (2019) -
NSC95397 is a Novel HIV Latency Reversing Agent
por: Nichols Doyle, Randilea, et al.
Publicado: (2023)